Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

271.62

+4.25 (1.59%)

as of Aug 21, 2026, 4:41:42 pm Market Open.

697 watching

Investor Insights

Aug 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown some volatility recently, primarily due to performance issues in its cardio business, despite reporting a solid beat-and-raise quarter. The company has successfully addressed past legal challenges related to talcum powder, minimizing the overhang of these lawsuits. Analysts are optimistic about JNJ’s upcoming earnings report expected on July 15, anticipating positive news about its oncology drugs and orthopedic business, although caution persists due to erratic stock movements following disclosure of results. The spin-off of the orthopedics division is viewed positively as it shifts focus towards higher-margin pharmaceutical and medical device sectors. Overall, JNJ is seen as a solid investment due to its strong drug pipeline and improved balance sheet, even as the company navigates its litigation concerns.

Consensus

Buy

Valuation

Fair Value

Similar

DON'T BUY

Has done better than the other US pharmaceuticals. The sector has not done well. This will be a tough hold because generics will give a lot of competition.

BUY

One of the best consumer product companies with a big medical exposure. Recent study indicated stents are no more effective than drugs, so the stock dropped. A great hedge against a weaker US economy.

TOP PICK

Feels you can get a double-digit return out of this one. Good opportunities for earnings improvement. Good price.

BUY

He likes it for the health care products, more than for the pharmaceutical and medical devices. The stent business is under serious question right now. Trades at a very reasonable PE.

DON'T BUY

Looking a lot better than it did, but still overvalued. His model price is $56.90. Negative 8% differential.

BUY

Likes this a lot. A multinational which pays a dividend.

BUY

A great company and well run. While diversified with pharmaceuticals and consumer products. Throws off lots of free cash flow.

HOLD

This is a company that will have lower return, but more stable. There is a good opportunity for a return in the future.

DON'T BUY

Model price of $57.07, a negative 14% differential. Typical of consumer staples where the market rotated into heavily this year.

BUY

Household products form a base for this company, and he sees the pharmaceuticals as an add-on. Excellent earnings.

BUY

Looks interesting. More consumer products than some of the other large pharmas.

DON'T BUY

His model price is $53.22 which is a negative 17% differential. If you want a great company in your portfolio for 20/30 years, this may be the one, or if you're trying to beat the S&P 500.

BUY

All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be.

DON'T BUY

The “gold standard” in the healthcare industry. The problem is when you look at earnings growth in healthcare it is the lowest and has the lowest expectations. Would avoid this sector.

BUY

A hybrid. Part pharmaceutical/medical devices and part consumer products. Just in the process of buying Pfizer's (PFE-N) consumers product division. Has had fabulous management. Great growth in earnings.

Showing 541 to 555 of 628 entries

Most Recent Experts

Darren Sissons

Campbell Lee & Ross

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Nick Mersch, CFA

Purpose Investments

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Liz Young, Head of investment strategy at SoFi

SoFi

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Johnson & Johnson (JNJ)